Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A window of opportunity trial evaluating safety and tolerability of the vandetanib-eluting radiopaque beads in patients with primary liver cancer and mCRC

Next Previous
Trial Profile

A window of opportunity trial evaluating safety and tolerability of the vandetanib-eluting radiopaque beads in patients with primary liver cancer and mCRC

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Colorectal cancer; Liver cancer
  • Focus Adverse reactions; First in man
  • Acronyms VEROnA
  • Sponsors BTG

    • Most Recent Events

    • 01 Feb 2022 Results (n=8) of an analysis assessing the role of RO beads as fiducial markers for stereotactic liver radiotherapy published in the British Journal of Radiology
    • 11 Oct 2017 New trial record
    • 09 Oct 2017 According to a BTG media release, first patient has been treated in this trial. This trial is supported by the Cancer Research UK Experimental Cancer Medicines Centre and the UCL Cancer Institute and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Centres for this trial are University College London Hospitals NHS Foundation Trust and the Royal Free Hospital NHS Foundation Trust.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top